INTRODUCTION
The fibrinolytic pathway in human plasma is initiated by activation of Hageman factor (1, 2) . The prealbumin fragments of active Hageman factor isolated from serum or derived experimentally from activated Hageman factor have been shown to activate a plasma protein, the plasminogen proactivator to the plasminogen activator, which in turn converts plasminogen to plasmin (3, 4) .
The plasma protein inhibitors, al antitrypsin, a2 macroglobulin (a2M),' and the inhibitor of the first component of complement (CTINH) Hageman factor deficient and plasma thromboplastin antecedent-(PTA) deficient plasma were supplied by Sera-Tec Biologicals, New Brunswick, N. J. Concentration was performed by ultrafiltration using UM-10 membranes (Amicon Corp., Lexington, Mass.) in 500 ml, 50 ml, or 10 ml capacity Amicons as appropriate. Plasma was prepared for the isolation of plasma proenzymes and inhibitors in ethylenediaminetetraacetate (EDTA) and polybrene as described (5) . The conversion of pre-PTA' (5, 6), prekallikrein (5), and plasminogen proactivator (3, 4) , by the Hageman factor fragments was measured by subsequent coagulation, bradykinin formation, and fibrinolysis, respectively. The C1INH was assessed functionally by its ability to inhibit the hemolytic activity of erythrocyte-bound C1 (EAC1) by either microtiter plate or tube titrations (7) and was quantitated by immunodiffusion (8, 9) . The titer of 1613 U per microgram of C1INH obtained is comparable to the activity in normal human serum (7) . al antitrypsin concentration was determined by quantitative immunodiffusion plates or by its inhibition of the esterase activity of trypsin upon BAPA as previously described (10). a2M concentration was determined utilizing quantitative immunodiffusion plates. ' In order to avoid ambiguity and confusion as to the state of activation of the molecule we have referred to the precursor of PTA as pre-PTA throughout the text. Other workers may consider PTA as the precursor form and refer to the activated molecule as activated PTA.
Isolation of components of the fibrinolytic pathway
Hageman factor fragments. Hageman factor prealbumin fragments were prepared by Quarternary aminoethyl (QAE) Sephadex chromatography followed by rechromatography on QAE Sephadex and were then fractionated by Sephadex G-100 gel filtration, as described in the accompanying paper (11) . The Hageman factor prealbumin fragments eluted on Sephadex G-100 at a mol wt of 32,500, were concentrated to approximately 20-25 Ag/ml, divided into aliquots, and stored at -70'C for routine use. Disc gel electrophoresis (12) revealed prealbumin bands with only trace contamination with albumin.
The intermediate sized Hageman factor fragment was isolated from human plasma as outlined in the accompanying paper (11) by QAE Sephadex chromatography followed by rechromatography on QAE Sephadex and was then fractionated by Sephadex G-100 gel filtration. The intermediate sized Hageman factor fragment eluted from Sephadex G-100 at a mol wt of 80,000 and was aliquoted and stored at -700C for further use. Assessment of the preparation by disc gel electrophoresis revealed two bands in the f-globulin region, one corresponding to the Hageman factor fragment and the other to a transferrin contaminant.
Plasminogen proactivator. The plasminogen proactivator was isolated by QAE Sephadex, Sulphoethyl (SE) Sephadex, and Sephadex G-150 chromatography as described (4, 11) . The plasminogen proactivator eluted from Sephadex G-150 at a mol wt of approximately 100,000 and was pooled, concentrated to 10 ml, and stored at -700C. The preparation contained trace prekallikrein and IgG contamination, when assessed by bioassay and Ouchterlony or alkaline disc gel electrophoresis, respectively.
Plasminogen. Plasminogen was prepared by affinity chromatography and Sephadex G-100 gel filtration as described (4, 13) . Disc gel electrophoresis revealed a single broad band identified as plasminogen by functional analysis of an unstained sliced replicate disc gel. There were no contaminating proteins detected. Plasmin was prepared by activating 500 Al of plasminogen (100,g/ml) with 50 Al (1, 500 U) of streptokinase for 30 min at 30'C and assayed on human fibrin plates (4).
Isolation of inhibitors of the fibrinolytic pathway al antitrypsin. 100 ml of plasma dialyzed against 0.0035 M phosphate buffer pH 7.8 were applied to a 5 X 100 cm column of QAE Sephadex equilibrated with the same buffer. The column was washed with 600 ml of equilibrating buffer and eluted with a linear salt gradient of 2,500 ml of equilibrating buffer and 2,500 ml of 0.0035 M phosphate buffer pH 7.8 containing 0.3 M sodium chloride. The column was run at 50 ml/h, and 10 ml fractions were collected. al antitrypsin was assayed by counterelectroimmunodiffusion (14) , utilizing undiluted anti-al antitrypsin antisera in all chromatographic procedures. The precipitin arcs observed were quantitated on a 0-4+ scale by inspection; al antitrypsin eluted between 0.07 and 0.15 M sodium chloride as shown in Fig. 1 . Tubes 220-245 were pooled so as to exclude much of the C1INH and a2M; the pool was concentrated to 20 ml by ultrafiltration, dialyzed for 5 h in 0.05 M sodium acetate buffer pH 5.0, and applied to a Sulphopropyl (SP) Sephadex column (3.5 X 30 cm) equilibrated with the same buffer. al antitrypsin was obtained in the effluent by washing the column with 200 ml of equilibrating buffer at 50 ml/h. The effluent fractions were pooled, adjusted to pH 7.45 Fig. 3 A. a2 macroglobulin. 100 ml of plasma dialyzed against 0.0035 M phosphate buffer pH 7.8 were applied to a QAE Sephadex (5 X 100 cm) column equilibrated with the same buffer. The column was washed with 600 ml of equilibrating buffer and eluted with a linear salt gradient of 2,500 ml of equilibrating buffer and 2,500 ml of 0.0035 M phosphate buffer pH 7.8 containing 0.3 M sodium chloride. The column was run at 50 ml/h, and 10 ml fractions were collected. a2M was assayed by counterelectroimmunodiffusion using undiluted anti-a2M antisera in all chromatographic procedures. The precipitin arcs observed were quantitated on a 0-4+ scale by inspection; a2M eluted between 0.05 and 0.10 M NaCl as shown in Fig. 1 . A pool containing a2M (tubes 170-212) was concentrated to approximately 4 ml and fractionated by upward flow at 10 ml/h utilizing a 5 X 100 cm column of Sepharose 6 B equilibrated with 0.0035 M phosphate buffer pH 7.8 containing 0.15 M NaCl. 10 ml fractions were collected per hour, and a2M eluted at 61% bed volume. The a2M peak was pooled, concentrated to 4.0 ml, -a, Antitrypsin -Albumin on alkaline disc gel electrophoresis in a region from which unstained gels yielded active C1INH upon elution (11) .
RESULTS
Inhibition of plasmin C1INH. 20 Al of plasmin (150 isg/ml) were incubated with 20 ,4 of decreasing concentrations of purified C1INH (45,000 U/ml) plus 20 Al of phosphate buffered saline pH 7.8 or with 40 Al of buffer alone for 30 min at 370C and the residual fibrinolytic activity determined. The preparation of plasmin with buffer alone generated 47 og/ml of plasmin. As indicated in Fig. 5 A, when the concentration of C1INH is increased, the effective plasmin is progressively inhibited.
al antitrypsin. 25 Al of plasmin (50 ,sg/ml) were incubated for 30 min at 370C with an equal volume of decreasing concentrations of purified al antitrypsin (2.1 mg/ml), having the same functional activity as an equal FIGURE 2 Disc gel electrophoresis of al tained by QAE Sephadex (Fig. 1 ), SP Sephadex G-100 chromatography.
antitrypsin obSephadex, and and fractionated by upward flow at 10 ml/h on a 5 X 100 cm column of Sephadex G-200 equilibrated with 0.0035 M phosphate buffer pH 7.8 containing 0.15 M NaCl. Fractionation was performed at 10 ml/h and 10 ml fractions were collected; a2M eluted at 30% bed volume. The a2M peak was pooled, concentrated to 30 ml, and stored at -40C for further use. This preparation contained no detectable C1INH, al antitrypsin, or inter-alpha trypsin inhibitor as assayed by counterelectroimmunodiffusion or Ouchterlony analysis and no detectable plasmin or plasminogen activator activity. Alkaline disc gel electrophoresis (Fig. 4) revealed one major band representing a2M as shown by elution of unstained replicate gels and analysis by counterelectroimmunodiffusion with undiluted anti-a2M antisera, as well as three minor bands. The isoelectric point of a2M determined by elution from sliced gels after isoelectric focusing was 6.4 as shown in Fig. 3 B. a2-macroglobulin and al-antitrypsin were not necessarily prepared from the same samples.
CIINH. The C1INH was purified by QAE Sephadex, SP Sephadex, Sephadex G-200, and Sephadex G-150 chromatography as described (11) . This preparation had no detectable al antitrypsin or a2M as assessed by Ouchterlony analysis, no detectable plasmin or plasminogen activator as assayed on human fibrin plates, and gave a double band volume of plasma when measured by trypsin inhibition (10), and the residual fibrinolytic activity determined. The preparation of plasmin with buffer alone yielded 24 Ag/ml of plasmin. As shown in Fig. 5 B, increasing concentrations of al antitrypsin resulted in a diminution of plasmin activity. The inhibitory activity of al antitrypsin upon plasmin, however, appeared relatively weak yielding only 36% inhibition at concentrations of al antitrypsin comparable to that of whole plasma in the presence of a plasmin concentration approximately 10% of the plasminogen concentration of whole plasma (16) . a2M. 50 Al of plasmin (100 isg/ml) were incubated with decreasing concentrations of a2M (247 Ig/ml) or buffer at 370C for 30 min, and the residual fibrinolytic activity determined. The control preparation of plasmin with buffer generated 52 Asg/ml of plasmin. As indicated in Fig. 6 , as the concentration of a2M increased, the residual fibrinolytic activity decreased proportionately. 45% inhibition was reached at an a2M concentration of 124 Ag/ml.
Utilizing 900,000 as the mol wt of a2M (16) and 80,000 as the mol wt of plasmin (16) , the number of moles of plasmin inhibited relative to the moles of a2M input was calculated. As shown in Fig. 7A , a straight line relating moles of plasmin inhibited to moles of a2M was obtained. By plotting the molar ratio of plasmin per a2M against moles of a2M input, a molar ratio approximating 2.0 was obtained for these reactants as indicated in Fig. 7 with an equal volume of C1INH (50,000 U/ml), a2M
(1.1 mg/ml) or phosphate-buffered saline pH 7.8 for 45 min at 370C. 20 Al of plasminogen (200 ,g/ml) were added to one of each duplicate mixture, incubated for 45 min at 370C, and the plasmin generated determined, while the other duplicate mixture was assayed for kallikrein. The mixtures containing plasminogen activator alone or plasminogen activator and C1INH generated 65 and 62 /Ag/ml of plasmin, indicating no inhibition of the plasminogen activator by C1INH. In contrast, the mixture containing plasminogen activator and a2M generated no detectable plasmin activity from plasminogen. The C1INH and a2M inhibited the kallikrein activity 70% and 75%, respectively. In order to establish that the apparent inhibition of plasminogen activator by a2M was not attributable to an effect on the assay for plasmin generated, this inhibitor as well as C1INH and al antitrypsin were chromatographically separated from the plasminogen activator after interaction of inhibitor with plasminogen activator. One-half milliliter of the concentrated QAE Sephadex effluent was incubated with 0.5 ml of buffer plus either 0.5 ml of CiINH (31 Ag/ml), a2M (1.1 mg/ml), al antitrypsin (2.1 mg/ml), or buffer for 30 min at 37°C. Each mixture was then dialyzed for 4.5 h with 0.0035 M phosphate buffer pH 7.8 and a 10 /l sample removed from each dialysate. Each mixture was then applied to a 2 X 10 cm column of QAE Sephadex, a 25 ml effluent obtained utilizing starting buffer, and the latter concentrated to 1.0 ml for assay of residual kallikrein and plasminogen activator activity. The results are presented in Table I . C1INH completely inactivated the kallikrein present in the original QAE Sephadex effluent, but had no effect upon the plasminogen activator. a2M inhibited both kallikrein and the plasminogen activator, whereas al antitrypsin revealed no inhibition of either enzyme.
The final QAE Sephadex effluent contained no detectable C1INH, a2M, al antitrypsin, or other plasmin inhibitors which might interefere with the assay for plasminogen activator or kallikrein. The loss of plasminogen activator and kallikrein as a result of dialysis and chromatography alone was less than 33%.
To examine the dose response effect of a2M, 0.5 ml of a QAE Sephadex effluent containing kallikrein and plasminogen activator was incubated with 0.5 ml of twofold falling dilutions of a2M (1.85 mg/ml), al antitrypsin (3 mg/ml), or buffer alone. The mixtures were dialyzed against 2,000 ml of 0.0035 M phosphate buffer pH 7.8 for 4.5 h and applied to 2 X 10 cm QAE Sephadex column equilibrated with the dialysis buffer. The columns were washed with 25 ml of equilibrating buffer, and each effluent concentrated to 0.5 ml for assay of residual kallikrein and plasminogen activator. The plasminogen activator in buffer or exposed to al antitrypsin generated 25 jug of plasmin from plasminogen (100 Ig/ml). The inhibition of plasminogen activator obtained with a2M ranged from 17% to 100% as shown in Fig. 8 . The inhibition of kallikrein by a2M was similar. The effluents tested contained no detectable plasmin or plasminogen. The effluent exposed to the highest concentration of a2M (1.85 mg/ml) yielded 10% inhibition of streptokinase activated plasminogen, suggesting that the peak inhibitory value of 100% at an a2M concentration of 1.85 mg/ml may be an overestimate.
Inhibition of Hageman factor fragments
In the accompanying paper (11) the ability of the C1INH to inhibit the action of the Hageman factor fragments upon its three substrates, prekallikrein, pre-PTA and plasminogen proactivator is demonstrated. To evaluate the effect of a2M (1.1 mg/ml) and al antitrypsin (2.1 mg/ml) on the ability of the Hageman factor frag- (3, 4) . Regulation of the fibrinolytic sequence previously recognized only in terms of the action of C1INH, al antitrypsin, and a2M on plasmin (17) (18) (19) is now extended to include the inhibition of the plasminogen activator by a2M and inhibition of the Hageman factor fragments by C1INH (11) .
The chromatographic isolation of each inhibitor was such that the final product was free of detectable contamination by the other two. On disc gel electrophoresis, the C1INH was free of other detectable proteins (11), the al antitrypsin contained albumin and two trace bands (Fig. 2) , and the a2M revealed three undefined bands (Fig. 4) . The isoelectric point of al antitrypsin was 5.2 ( Fig. 3 A) and of a2M was 6.4 ( Fig. 3 B) . Functional analysis of the C1INH revealed that the number of effective molecules/microgram of protein was consistent with that observed in whole serum (7) . The concentration of al antitrypsin measured by immunodiffusion analysis of the purified preparation required to inhibit the esterolytic activity of trypsin was approximately twice an identical antigenic amount of cal antitrypsin in normal plasma. The finding that 1 mol of a2M inhibited 2 mol of plasmin (Fig. 7) attested to the functional integrity of the purified protein.
The capacity of the C1INH to prevent the action of the Hageman factor fragments in converting the plasminogen proactivator to plasminogen activator is noted in the companion study and extends to inhibition of prekallikrein and pre-PTA activation as well (11) . The concentration of C1INH effective in this regard did not interfere with the action of the immediate conversion products and subsequent steps involved in completion of each biologic reaction sequence. In comparable experiments neither al antitrypsin nor a2M inhibited the ability of the Hageman factor fragments to convert plasminogen proactivator, prekallikrein, or pre-PTA to their respective active enzymes.
In order to study the inhibition of the plasminogen activator it was necessary to minimize the concentration of the inhibitors during the subsequent assay of the residual plasminogen activator activity. Thus, the reactants were subjected to QAE Sephadex chromatography and the active enzymes sought in the fractions in which they were identified after exposure to buffer alone. The recovery of plasminogen activator or kallikrein in buffer alone was 67% and the value was similar upon interaction with al antitrypsin. Thus the lack of recovery with a2M and C1INH pretreatment was attributed to inhibition of the active enzyme. Carry over of inhibitory material was excluded by both functional and Ouchterlony analysis. With this experimental design it was established that a2M inhibited the plasminogen activator in a dose response fashion (Fig. 8) , the effect being quite comparable to the inhibition of kallikrein. Although the protein concentration of the two enzymes in the experiment is not known, it is noteworthy that they were both derived from their precursors by activation with Hageman factor fragments of a plasma fraction known to contain all of each proenzyme which can be derived from plasma. Further, the concentration of a2M yielding 100% inhibition is in good agreement with its concentration in normal plasma. When the same source of proenzymes was activated and the inhibitory effect of cx2M compared with C1INH and axl antitrypsin, only a2M inhibited the plasminogen activator (Table I) . Both a2M and C1JNH were active against kallikrein, while al antitrypsin failed to inhibit either enzyme. Inhibition of kallikrein by al antitrypsin observed by others involved longer incubation times (20) or less pure preparations of al antitrypsin (21) . The failure of C1INH to prevent the action of plasminogen activator is not only in contradistinction to its effect on kallikrein, but also to its ability to inhibit PTA (22) .
Inhibition of the fibrinolytic activity of plasmin by C1INH (17) and inhibition of the caseinolytic activity of human plasmin by al antitrypsin (18) and by a2M (19) have been previously observed. Utilizing highly purified preparations of each inhibitor, a dose response type inhibition (Figs. 5 A, 5 B, and 6) was noted upon the fibrinolytic activity of plasmin. The concentration of al antitrypsin and C1INH required for these experiments represented falling dilutions of a concentration approaching that in plasma, whereas a2M had a similar activity beginning at one-tenth its plasma concentration. The inhibition appeared to be stoichiometric with one molecule of a2M inhibiting two molecules of plasmin (Fig. 7) , a result similar to that obtained by Ganrot (19) in examining trypsin inhibition by a2M. Using casein as a substrate for plasmin, Ganrot (19) determined an equimolar binding ratio between a2M and plasmin.
To summarize, C1INH is the only factor active upon the Hageman factor fragments, functioning at the initial step of the fibrinolytic pathway. a2M appears to be the other critical inhibitor of the fibrinolytic pathway, being the only factor active against the plasminogen activator and the most active inhibitor of plasmin.
